Steroid-Sparing Management of Facial Dermatoses: The Role of Calcineurin Inhibitors and Other Single Agents

Facial dermatoses such as atopic dermatitis (AD), seborrheic dermatitis (SD), rosacea, perioral dermatitis (POD), and acne vulgaris are highly prevalent and often coexist in overlapping clinical presentations. Management of these conditions frequently requires multiple topical medications, which can negatively impact adherence and increase costs. This challenge has led to the frequent use of combination topical creams, many of which contain corticosteroids, antifungals, and antibacterials in a single formulation. Despite widespread use, the efficacy of these combination creams in mixed or undifferentiated facial dermatoses is poorly supported by evidence and can result in inappropriate corticosteroid exposure and disease exacerbation. To address the need for evidence-based alternatives, we conducted a systematic synthesis of published studies evaluating topical agents with broad-spectrum efficacy for facial dermatoses. We reviewed the studies included in the provided dataset to identify agents with the most evidence supporting multi-condition use and to evaluate their safety and efficacy profiles. Pimecrolimus 1% cream demonstrated the broadest coverage, being evaluated in 15 unique facial dermatoses, including atopic dermatitis, seborrheic dermatitis, rosacea, perioral dermatitis, steroid-induced dermatitis, pityriasis alba, and acneiform eruptions. Tacrolimus 0.1% and 0.03% ointments demonstrated activity in fewer conditions, with two distinct indications each. The analysis also identified other agents, such as azelaic acid, metronidazole, ivermectin, and newer molecules such as ruxolitinib, each studied in one to three specific dermatoses. These findings suggest that pimecrolimus may represent the most versatile topical therapy across diverse facial dermatoses, while highlighting the need for clinicians to avoid non-evidence-based combination creams in favor of single agents with proven safety and efficacy. Future randomized controlled trials are needed to confirm these observations and assess whether broad-spectrum topicals can reduce unnecessary corticosteroid exposure.